Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Example Group: Participants_in_Anticoagulation_for_COVID_19_Combined_ATTACC_ACTIV_4a_and_REMAP_CAP_RCT_hospitalized_not_critically_ill

Generated Narrative: Group 7750

version: 8; Last updated: 2023-12-05 12:59:21+0000

Artifact related artifact: No display for RelatedArtifact (type: cite-as; citation: Participants in Anticoagulation for COVID-19 Combined (ATTACC, ACTIV-4a, and REMAP-CAP) RCT (hospitalized, not critically ill) [Group]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 7750. Revised 2022-01-11. Available at: https://fevir.net/resources/Group/7750. Computable resource at: https://fevir.net/resources/Group/7750.)

Artifact Author: Brian S. Alper:

url: https://fevir.net/resources/Group/7750

identifier: FEvIR Object Identifier/7750

name: Participants_in_Anticoagulation_for_COVID_19_Combined_ATTACC_ACTIV_4a_and_REMAP_CAP_RCT_hospitalized_not_critically_ill

status: Active

date: 2022-01-11 17:20:56+0000

publisher: Computable Publishing LLC

contact: support@computablepublishing.com

description:

An enumerated group participating in a randomized trial.

copyright:

https://creativecommons.org/licenses/by-nc-sa/4.0/

type: Person

membership: Enumerated

quantity: 2244

combinationMethod: All of

characteristic

code: Research Study for which this is the observed sample

value: Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19 [Journal Article]. Contributors: The ATTACC, ACTIV-4a, and REMAP-CAP Investigators. In: The New England Journal of Medicine, DOI 10.1056/NEJMoa2105911. Published August 04, 2021. Available at: https://doi.org/10.1056/NEJMoa2105911.

exclude: false

description:

Participant in the Anticoagulation for COVID-19 Combined (ATTACC, ACTIV-4a, and REMAP-CAP) RCT

characteristic

code: Admission to establishment (procedure)

value: Hospital admission

exclude: false

description:

Hospitalized

characteristic

code: Disease (disorder)

value: ATTACC and ACTIV-4a limited inclusion to patients with confirmed COVID-19 (and excluded initially entered participants who did not have confirmed SARS-CoV-2. REMAP-CAP however included patients with confirmed COVID-19 or suspected COVID-19 with intent to test for COVID-19.

exclude: false

description:

COVID-19

characteristic

code: Severity

value: severe disease defined as ICU-level care or critically ill where ICU-level care was defined as the use of respiratory or cardiovascular organ support (oxygen delivered by high-flow nasal cannula, noninvasive or invasive mechanical ventilation, or the use of vasopressors or inotropes)

exclude: true

description:

not critically ill